pharmacology

pharmacology

pharmacology

Link the consumption of lorazepam in the series 'The White Lotus' with an increase in Google searches for this anti-anxiety drug

According to a study published in the journal JAMA Health Forum, the use of the benzodiazepine lorazepam by the character Victoria Ratliff in the series The White Lotus was associated in the United States with an increase in Google searches for this medication, including queries about how to obtain it online. The series generated 1.6 million more searches than usual over a 12-week period. Although the study reflects searches for information and not actual consumption, the abuse of anti-anxiety drugs is a fact: illegal sales of benzodiazepines have increased in the United States, and Spain leads the rankings in terms of consumption.

 

 

0

Using beta blockers does not benefit patients who have survived a heart attack with normal cardiac function, according to a new study

A meta-analysis concludes that the use of beta-blockers is not necessary in patients who have suffered a heart attack but have normal cardiac function. The research, coordinated in Spain by the CNIC, brings together data from five clinical trials and 17,801 patients. One of these trials, REBOOT, already showed that patients who did not have reduced cardiac function after a heart attack did not benefit from treatment with beta blockers. According to this recent meta-analysis, published in the New England Journal of Medicine and presented at the American Heart Association Congress in New Orleans (USA), the use of these drugs does not reduce mortality, reinfarction or heart failure in this group of patients.

0

A review confirms major differences in the cardiometabolic side effects of 30 antidepressants

Different antidepressant drugs cause different side effects in the body, in parameters such as heart rate, blood pressure or body weight, according to a meta-analysis published by The Lancet. For example, agomelatine administration is associated with weight loss, while other molecules such as maprotiline are associated with weight gain. The research brings together 151 studies and 17 reports from the US Food and Drug Administration (FDA), including more than 58,000 people and comparing 30 antidepressant drugs with a placebo.

0

A review questions the efficacy of the painkiller tramadol for chronic pain

Tramadol is a painkiller prescribed for chronic pain and is considered safer than other opioids. A systematic review with meta-analysis that included 19 clinical trials with more than 6,500 people showed that, although it relieved pain, the effect was small and below what would be considered clinically effective. In addition, the analysis indicated that the drug is likely to increase serious adverse events, particularly cardiac events. Although an increased risk of some types of cancer was also detected, the authors question this effect due to the short follow-up period. ‘Given the limited analgesic benefits and increased risk of harm, the use of tramadol for chronic pain should be reconsidered, with preference given to safer alternatives and additional high-quality trials to clarify its risk-benefit profile,’ the researchers note in the study, published in BMJ Evidence Based Medicine.

 

0

The European Association for the Study of Obesity recommends semaglutide and tirzepatide as first-line treatment for obesity

An article published in Nature Medicine outlines the new framework for pharmacologically treating obesity and its complications established by the European Association for the Study of Obesity (EASO). The new guidelines establish semaglutide and tirzepatide as first-line treatment for this disease and most associated conditions. The team of authors, with Spanish participation, reviewed the scientific evidence on the effects of drugs on total weight loss and its complications and designed an algorithm to help medical personnel guide treatment, taking into account each patient's medical history and the action profiles of available medications.

0

Controversy over the Trump administration's proposal of leucovorin as a treatment for autism

At a press conference at the White House on Monday, Donald Trump and health authorities linked the use of paracetamol during pregnancy to cases of autism. They also recommended leucovorin as a treatment for autism. Immediately afterwards, the US Food and Drug Administration (FDA) announced in a press release that it had begun the approval process for calcium leucovorin tablets for patients with cerebral folate deficiency. “People with cerebral folate deficiency have been observed to have developmental delays with autistic characteristics, seizures, and movement and coordination problems,” they said. The update on the use of the drug, discussed by the scientific community, will authorize the treatment of children with autism spectrum disorder.

 

0

US health authorities will warn of a link between paracetamol use during pregnancy and the risk of autism in children, according to 'The Washington Post'

On Monday, US federal health authorities will advise pregnant women against taking paracetamol in the early stages of pregnancy, unless they have a fever, as reported yesterday by The Washington Post. The announcement will be accompanied by a recommendation for a drug called leucovorin as a treatment for autism, the article adds. Donald Trump said yesterday: ‘Tomorrow we are going to have one of the most important announcements... from a medical standpoint, I think, in the history of our country. I think we have found an answer to autism.’

0

Drug identified as “near-universal” treatment for rare disease

Most rare diseases are caused by mutations in DNA, but the same gene can mutate in different ways, which complicates treatment. Now, a team from the CRG in Barcelona has shown that an already approved drug is capable of stabilising almost all mutated versions of a human protein—specifically, the vasopressin V2 receptor, which is linked to a rare disease called nephrogenic diabetes insipidus. According to the researchers, who published their findings in Nature Structural & Molecular Biology, the study is the first proof of concept demonstrating that a drug can act as a ‘near-universal’ treatment, which could accelerate the development of therapies.

 

0

Semaglutide has “unexpected” effects on muscle function in mice

In mice, administering semaglutide - the molecule marketed under the name Ozempic or Wegovy - does not reduce muscle mass as much as expected, but it does affect muscle function, according to a study published in Cell Metabolism. In some types of muscle, the experiment measured a decrease in force-generating capacity of about 20%, disproportionately greater than the loss of muscle mass.

0

An antipsychotic proves effective in treating schizophrenia when taken orally weekly rather than daily

An oral formulation of risperidone could be administered weekly instead of daily to treat patients with schizophrenia with the same efficacy, according to a phase III clinical trial published in The Lancet Psychiatry. The study included 83 patients in the United States.

 

0